What's in dr hab. n. med. Agnieszka Wierzbowska's pipeline?

dr hab. n. med. Agnieszka Wierzbowska has 4 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with dr hab. n. med. Agnieszka Wierzbowska's portfolio?

Top competitors by shared drug class: Agendia, Asan Medical Center, Children's Cancer Group, China, China Breast Cancer Clinical Study Group, Fujian Medical University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dr-hab-n-med-agnieszka-wierzbowska.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

dr hab. n. med. Agnieszka Wierzbowska — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dr hab. n. med. Agnieszka Wierzbowska pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
DAC	DAC	marketed	Cytidine deaminase inhibitor	Cytidine deaminase	Oncology
Consolidation, III HiDAraC cycle	Consolidation, III HiDAraC cycle	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA/RNA synthesis (cytidine deaminase inhibition pathway)	Oncology
Consolidation, I HAM cycle	Consolidation, I HAM cycle	phase 3	Chemotherapy combination regimen		Oncology
II Consolidation HiDAraC	II Consolidation HiDAraC	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA synthesis (cytidine deaminase inhibition pathway)	Oncology

Therapeutic area mix

Oncology · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Agendia · 1 shared drug class
Asan Medical Center · 1 shared drug class
Children's Cancer Group, China · 1 shared drug class
China Breast Cancer Clinical Study Group · 1 shared drug class
Fujian Medical University · 1 shared drug class
MIPO Clinic · 1 shared drug class
Nanjing Yoko Biomedical Co., Ltd. · 1 shared drug class
AGO Study Group · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for dr hab. n. med. Agnieszka Wierzbowska:

Cite this brief

Drug Landscape (2026). dr hab. n. med. Agnieszka Wierzbowska — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dr-hab-n-med-agnieszka-wierzbowska. Accessed 2026-05-17.